MedTrace Logo

Quantitative MRI in Assessing Disease in Patients With Brain Tumors

NCT02269111 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2018-05-29

No results posted yet for this study

Summary

This pilot clinical trial studies quantitative magnetic resonance imaging (MRI) at 3 Tesla in assessing disease in patients with tumors that have spread to the brain (brain metastases). In addition to routine care brain imaging of the brain, this study will include advanced multiparametric MRI sequences to measure vascular, cellular, and molecular properties of the tumor. Performing extra scans during MRI provides more information about the metastases and may better predict treatment response.

Conditions

  • Tumors Metastatic to Brain
  • Unspecified Adult Solid Tumor, Protocol Specific

Interventions

PROCEDURE

diffusion-weighted magnetic resonance imaging

Undergo DW-MRI

PROCEDURE

chemical exchange saturation transfer magnetic resonance imaging

Undergo CEST-MRI

PROCEDURE

dynamic contrast-enhanced magnetic resonance imaging

Undergo DCE-MRI

PROCEDURE

dynamic susceptibility contrast-enhanced magnetic resonance imaging

Undergo DSC-MRI

Sponsors & Collaborators

  • National Cancer Institute (NCI)

    collaborator NIH

  • Vanderbilt-Ingram Cancer Center

    lead OTHER

Principal Investigators

  • Albert Attia, MD · Vanderbilt-Ingram Cancer Center

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2017-10-31
Completion
2018-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02269111 on ClinicalTrials.gov